Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Unicycive Therapeutics appointed Meredith S. Manning as an independent director to its board, effective October 1, 2026. Ms. Manning, who previously served as Chief Commercial Officer of Soleno Therapeutics, will also serve as Chairperson of the Nominating and Corporate Governance Committee. The company also announced the resubmission of its New Drug Application for Oxylanthanum Carbonate with a new manufacturing vendor.
Soundthinking Signs $114M M&A Deal with Transom Capital Group, LLC
SoundThinking, Inc. has entered into a definitive agreement to be acquired by Transom Capital Group via a tender offer for $8.00 per share in cash plus a contingent value right (CVR) worth up to $3.00. The deal implies an upfront enterprise value of approximately $114 million, representing a 46% premium to the company's prior closing price, and will result in SoundThinking becoming a private company.
Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.
Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.
Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors as a Class I director, effective October 14, 2026. Mr. Daly, a veteran life sciences executive with experience at AstraZeneca and Takeda, will receive an initial grant of 57,000 stock options as part of his non-employee director compensation package.
JELD-WEN Holding $135M Debt Financing with Commitment Parties
JELD-WEN entered into a commitment and consent letter with holders of 94.5% of its 2027 Senior Notes and 72.2% of its 2028 Term Loans to refinance and extend debt maturities to 2031. The transaction includes a $135 million new money debt financing to provide incremental liquidity and support the company's business plan. The agreement also involves exchange offers and consent solicitations to eliminate restrictive covenants and modify existing debt terms.
1 800 Flowers Com Divestiture to PlanetArt, LLC for $45M
1-800-FLOWERS.COM, Inc. has entered into a definitive agreement to sell its Personalization Businesses, including PersonalizationMall.com and Things Remembered, to PlanetArt, LLC for $45 million in cash. The divestiture is intended to sharpen the company's portfolio focus on its primary brands and strengthen its financial position for strategic growth initiatives. The parties also plan to enter into a commercial agreement allowing 1-800-FLOWERS.COM to continue offering select personalized products to its customers post-closing.
Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from the previous range of $350 million to $370 million. The increase is driven by strong U.S. demand for its cancer therapies Amtagvi and Proleukin, representing approximately 60% annual growth.
Sherwin Williams $750M Debt Financing with Citibank, N.A.
Sherwin-Williams entered into a new $750 million senior unsecured 364-day term loan credit agreement with Citibank as administrative agent. The proceeds will be used to refinance an existing 2025 credit agreement and for general corporate purposes, including working capital. The agreement includes a financial covenant requiring a consolidated leverage ratio of no more than 3.75 to 1.00.
Altimmune, Inc. appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Mr. Menziuso joins from Centessa Pharmaceuticals and succeeds Gregory Weaver in the Principal Accounting Officer role, though Weaver remains the company's Chief Financial Officer.
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.
CarMax reported second quarter fiscal 2027 results with total net revenues rising 19.5% to $7.9 billion and net earnings per diluted share increasing 81.3% to $1.16. The company saw a 14.7% increase in combined retail and wholesale unit sales and announced plans to resume share repurchases in the third quarter of fiscal 2027.
Term
Q2 2027
Earnings call
Sep 29, 2026, 8:00 AM ET
“Our strong second quarter results reflect solid execution and early progress against Shift into GEAR, our four-pillar strategy to strengthen CarMax’s core business and return the company to sustained growth. We delivered 81% EPS growth as we strengthened our price competitiveness, increased Extended Protection Plan margins, expanded CAF’s share of Tier 2 originations, continued to enhance our digital experience, and drove material SG&A leverage. I am confident in our ability to build on this early momentum. We have a clear strategy, a solid foundation, and an exceptional team accelerating our progress to create long-term value for our shareholders.”
CID Holdco Signs $65M M&A Deal with Envoy Technologies, Inc.
CID HoldCo, Inc. entered into a definitive Securities Purchase Agreement to acquire 100% of Envoy Technologies, Inc. from BladeRanger Ltd. for $65 million in stock. The consideration consists of approximately 10.8 million shares of common and Series C preferred stock valued at a reference price of $6.00 per share, including shares allocated to settle a $12.5 million convertible note.
Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.
T1 Energy $50M Debt Financing with qualified institutional buyer
T1 Energy Inc. entered into a note purchase agreement to sell an additional $50.0 million in 4.75% Convertible Senior Notes due 2031 to an existing shareholder. The notes are an add-on to an existing series, bringing the total outstanding principal to $170.0 million. Proceeds will be used to fund infrastructure and equipment for Phase 1 of the G2_Austin solar cell fab and for general corporate purposes.
Alzamend Neuro presented Phase 1/2A clinical trial data for AL001, a novel organic lithium salt, at the ISMRT Conference. The study utilized 7T MRI imaging to evaluate brain pharmacokinetics, demonstrating that AL001 is designed for improved brain delivery with lower systemic exposure compared to standard inorganic lithium salts.
Westlake Corporation announced it will cease operations at its PVC production plant in Cologne, Germany, to optimize its European chlorovinyls footprint and improve profitability. The closure, expected in Q1 2027, will result in a workforce reduction of approximately 120 employees and total pre-tax charges of approximately $205 million. The company also provided a business update noting that Q3 2026 financial performance is expected to be sequentially lower than Q2 2026 due to challenging market conditions.
Uranium Energy Corp reported its fiscal year 2026 results, highlighting a transformational year as it transitioned into a multi-mine U.S. producer with production at Christensen Ranch and Burke Hollow. The company sold 400,000 pounds of uranium at a realized price of $93.13 per pound and ended the year with $753 million in liquid assets and no debt.
Liberty Star Uranium & Metals Debt Financing Update with Monroe Street Capital Partners LP
Liberty Star Uranium & Metals Corp. entered into a securities purchase agreement with Monroe Street Capital Partners LP for a convertible promissory note in the principal amount of $95,700. The note includes a 10% original issue discount, bears 8% interest, and matures in one year. The debt is convertible into shares of the company's common stock.
Stewards Signs $90M M&A Deal with Envy Development DE, LLC and Envy Recreational, LLC
Stewards, Inc. completed the acquisition of Envy Development DE, LLC and Envy Recreational, LLC, which own the real estate assets of Envy Pompano Beach, for an aggregate purchase price of $90.0 million. The consideration consisted of $44.6 million in refinanced debt, $42.8 million in common stock (14,263,025 shares), and a $2.0 million unsecured promissory note. A portion of the shares (7 million) were placed in escrow to be redeemed for cash payments of $3.0 million monthly starting in October 2026.
Value
$90M
Counterparty
Envy Development DE, LLC and Envy Recreational, LLC
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of newly designated Class A Convertible Preferred Stock. The preferred shares are priced at a common stock equivalent of $18.3561 per share and will be used to support the development of ivonescimab, including new clinical collaborations with AstraZeneca's oncology portfolio.
Value
$2B
Counterparty
AstraZeneca Holdings B.V.
“This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab. We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab. With a growing body of evidence supporting ivonescimab’s differentiated PD-1 / VEGF bispecific approach, we look forward to further broadening the development plan of ivonescimab and initiating new clinical trials exploring the potential to combine ivonescimab with promising novel anti-cancer compounds, including ADCs, to bring together complementary approaches to tumor-cell killing, antitumor immunity, and the tumor microenvironment.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
VerifyMe, Inc. provided a status update on its pending merger with Open World Ltd. by filing required pro forma financial information and audited financial statements for the target company as requested by Nasdaq. The transaction, originally announced in February 2026, involves Open World becoming a wholly owned subsidiary of VerifyMe.
Futurewave Acquisition Signs $400M M&A Deal with Olympian Group Inc.
Futurewave Acquisition Corporation (FWAC), a SPAC, has entered into a definitive merger agreement to acquire Olympian Group Inc., a Hong Kong-based provider of integrated chip and electronic component solutions. The transaction values Olympian at an agreed net value of $400 million, with Olympian shareholders receiving 40 million shares of the combined company at $10.00 per share. Upon closing, the combined entity is expected to remain listed on the Nasdaq Stock Market.
AAR CORP. has entered into a definitive agreement to acquire a 65% controlling interest in MRO Holdings for approximately $2.6 billion in cash and preferred stock. The deal creates the world's largest heavy maintenance MRO provider, adding over $1 billion in annual revenue and significantly expanding AAR's EBITDA margins. The transaction is expected to close in the third fiscal quarter ending February 2027.
Value
$2.6B
Counterparty
MRO Holdings, Inc.
“Through the acquisition of MRO Holdings, we will create the largest heavy maintenance MRO in the world, servicing a combined total of nearly 3,000 aircraft per year in our hangars. As a result of this scale, we expect to drive additional volume through our Component MRO facilities, we will have a much larger channel for new and existing OEM distribution relationships, and we will have additional avenues for data collection supporting our software business.”
John M. Holmes, Chairman, President and CEO of AAR
“The transaction structure allows us to partner with a proven team that brings decades of experience in a strategically important region. This structure also provides the financial flexibility to continue to pursue AAR’s broader strategy. This highly strategic acquisition is truly transformational for AAR and marks a significant step in our long-term growth plan.”
John M. Holmes, Chairman, President and CEO of AAR
Korn Ferry held its 2026 Annual Meeting of Stockholders where shareholders elected nine directors, approved executive compensation, and ratified Ernst & Young LLP as auditors. Additionally, stockholders approved the Amended and Restated 2022 Stock Incentive Plan, which increases the share pool by 1,400,000 shares and extends the plan term to 2036.
Quantum-Si Incorporated filed a formal investor presentation deck (Exhibit 99.1) titled 'Proteus: The Future of Single-molecule Protein Sequencing' for use at the World HUPO 2026 conference in Singapore. The presentation provides updates on the development and commercialization of the Proteus platform, including its amino acid detection capabilities and system integration progress.
News Corp provided a daily update on its $1 billion stock repurchase program, which authorizes the buyback of Class A and Class B common stock. The filing includes mandatory daily disclosures required by the Australian Securities Exchange (ASX) regarding recent repurchase transactions. The program was originally authorized on July 15, 2025, and allows for open-market repurchases based on market conditions.
NETSOL Technologies reported record fiscal year 2026 revenue of $74.4 million, a 12.5% increase year-over-year, exceeding its previous guidance. The company achieved full-year profitability with GAAP net income of $2.95 million and nearly doubled its operating income to $6.9 million.
George Kollitides resigned from the Board of Directors of D. Boral Acquisition I Corp. effective September 23, 2026. The resignation was for personal reasons and did not involve any disagreements with the company's operations, policies, or practices.